Literature DB >> 16781226

Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention.

Huseyin Uyarel1, Nese Cam, Ertan Okmen, Hulya Kasikcioglu, Zeynep Tartan, Ozgur Akgul, Dilek Simsek, Mustafa Cetin, Emrah Bozbeyoglu, Ali Buturak, Bulent Uzunlar.   

Abstract

BACKGROUND: The presence of Q waves at presentation with a first acute ST-segment elevation myocardial infarction (STEMI) reflects a more advanced stage of the infarction. Resolution of ST-segment elevation indicating successful myocyte reperfusion may differ according to how far the infarction process has progressed. The Selvester QRS score measures infarct size. The purpose of this study was to evaluate the predictive value of QRS score on ST-segment resolution and 30-day clinical outcomes in patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI).
METHODS: We conducted a prospective cohort study in 112 consecutive patients (mean age 57 +/- 11 years, 94 men, 18 women) with first acute STEMI of <12-hour onset who underwent successful (TIMI-3 flow) primary PCI. The Selvester QRS score was estimated on the first electrocardiogram (ECG) after hospital admission. Sum of ST-segment elevation amount in millimeters was obtained immediately before angioplasty and 60 minutes after the restoration of TIMI-3 flow. The difference between 2 measurements was accepted as the amount of ST-segment resolution and expressed as summation sigmaSTR. summation sigmaSTR <50% was accepted as ECG sign of no-reflow phenomenon. Follow-up to 30-day was performed.
RESULTS: The no-reflow phenomenon was more often observed in patients with high QRS score (> or = 4) than in those with low QRS score (34.4% and 6.3%, P < .001). Thirty-day composite major adverse cardiac event (MACE) rate was 14% in patients with high QRS score versus 0% in low QRS score group (P = .007). After adjusting for baseline characteristics, high QRS score remained a strong independent predictor of no-reflow (OR 4.1, 95% CI 1.5-10.7, P = .005) and MACE (OR 1.8, 95% CI 1.1-2.9, P = .011).
CONCLUSIONS: The presence of high QRS score is an independent predictor of incomplete ST recovery and 30-day MACE in STEMI treated with primary PCI.

Entities:  

Mesh:

Year:  2006        PMID: 16781226     DOI: 10.1016/j.ahj.2006.03.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Acute hyperglycemia causes microvascular damage, leading to poor functional recovery and remodeling in patients with reperfused ST-segment elevation myocardial infarction.

Authors:  Katsuhiko Sarazawa; Akira Nakano; Hiroyasu Uzui; Yasuhiko Mitsuke; Tohru Geshi; Hidehiko Okazawa; Takanori Ueda; Jong-Dae Lee
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

2.  Relationship between Selvester ECG Score and Cardiovascular Outcomes in Patients with Non-ST Elevation Myocardial Infarction.

Authors:  Osman Can Yontar; Guney Erdogan; Mustafa Yenercag; Sefa Gul; Ugur Arslan; Ali Karagoz
Journal:  Acta Cardiol Sin       Date:  2021-11       Impact factor: 2.672

Review 3.  Unmet goals in the treatment of Acute Myocardial Infarction: Review.

Authors:  Alejandro Farah; Alejandro Barbagelata
Journal:  F1000Res       Date:  2017-07-27

4.  Both baseline Selvester QRS score and change in QRS score predict prognosis in patients with acute ST-segment elevation myocardial infarction after percutaneous coronary intervention.

Authors:  Qian Liu; Yong Zhang; Pengqiang Zhang; Junbo Zhang; Xiaojiao Cao; Shanshan He; Donghui Yang
Journal:  Coron Artery Dis       Date:  2020-08       Impact factor: 1.717

5.  Effect of coronary collateral circulation on the prognosis of elderly patients with acute ST-segment elevation myocardial infarction treated with underwent primary percutaneous coronary intervention.

Authors:  Ai-Ai Chu; Wei Li; You-Qi Zhu; Xiao-Xue Meng; Guo-Yong Liu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.